RRx-001, A novel dinitroazetidine radiosensitizer
Open Access
- 3 February 2016
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 34 (3) , 371-377
Abstract
Summary: The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.Keywords
This publication has 31 references indexed in Scilit:
- Ionizing radiation-induced metabolic oxidative stress and prolonged cell injuryCancer Letters, 2012
- Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic MaterialsCancer Research, 2012
- New uses for old drugsNature, 2007
- The chemoradiation paradigm in head and neck cancerNature Clinical Practice Oncology, 2007
- The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapyExpert Opinion on Therapeutic Targets, 2006
- The HIF pathway in cancerSeminars in Cell & Developmental Biology, 2005
- 1,3,3-Trinitroazetidine (TNAZ), a melt-cast explosive: synthesis, characterization and thermal behaviourJournal of Hazardous Materials, 2004
- Design and Synthesis of Energetic MaterialsAnnual Review of Materials Research, 2001
- A Short History Of Nitroglycerine And Nitric Oxide In Pharmacology And PhysiologyClinical and Experimental Pharmacology and Physiology, 2000
- Regioselective formation of a misonidazole-glutathione conjugate as a function of pH during chemical reductionBiochemical Pharmacology, 1988